Ascendis Pharma Stock (NASDAQ:ASND)


ForecastOwnershipChartTranscripts

Previous Close

$202.00

52W Range

$118.03 - $216.45

50D Avg

$200.10

200D Avg

$169.19

Market Cap

$12.31B

Avg Vol (3M)

$469.15K

Beta

0.41

Div Yield

-

ASND Company Profile


Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia. In addition, the company develops TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/g for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Yes

Country

DK

Employees

1,017

IPO Date

Jan 28, 2015

Website

ASND Performance


Latest Earnings Call Transcripts


Q2 25Aug 09, 25 | 4:30 PM
Q1 25May 01, 25 | 4:30 PM
Q4 24Feb 12, 25 | 4:30 PM

Peer Comparison


TickerCompany
ROIVRoivant Sciences Ltd.
BAXBaxter International Inc.
RPRXRoyalty Pharma plc
EXELExelixis, Inc.
BBIOBridgeBio Pharma, Inc.
MRNAModerna, Inc.
IONSIonis Pharmaceuticals, Inc.
SMMTSummit Therapeutics Inc.
BMRNBioMarin Pharmaceutical Inc.
MDGLMadrigal Pharmaceuticals, Inc.